Hemlibra Ambassador Fireside Chat

Wednesday, August 30, 6:00 PM EDT

*Indicates a required field

Genentech and its agents will collect your name and contact information in order to facilitate your registration. You can find additional information about our privacy practices at https://www.gene.com/privacy-policy.

First Name*

Last Name*

Email Address*

Confirm Email Address*

Phone Number*

Zip Code*

What best describes you?*

Are you or your loved one currently on HEMLIBRA?*

Will any guests be participating in the event with you? How many?

For additional Genentech support services:

Our Hemophilia Community Clinical Education Managers (CEMs) have years of experience as registered nurses and are ready to help. Once you’re signed up, you’ll hear from a CEM serving your area shortly. You’ll also receive a few helpful emails with information about HEMLIBRA, treatment tips, financial support, updates, and more:

I wish to receive information that may be of interest to me from Genentech and its affiliates about products, services, including co-pay assistance or other patient support, opportunities to participate in surveys or provide feedback, or other topics (including information about diseases or conditions). I may be contacted by mail or email using the information I’ve provided. By asking to receive this information, I understand my personally identifiable information will be used and disclosed by Genentech, its successors, its agents, and as otherwise required by law. I understand providing this agreement is voluntary and plays no role in getting my medicine. I also understand that I may opt out of receiving this information at any time by calling 877-436-3683.

By checking this box, I consent to receive autodialed calls and text messages, which may include marketing communications, from and on behalf of Genentech at the phone number(s) provided regarding HEMLIBRA. I understand that consent is not a requirement of any purchase or enrollment. Message frequency may vary. Message and data rates may apply. I may opt out at any time by texting STOP or calling 877-436-3683. I am also agreeing to the Privacy Policy and SMS Terms & Conditions.

Me gustaría recibir apoyo adicional de Genentech en español.

Cancel

Location

Online Webinar

Speaker(s)

Christine Pelayo

Clinical Education Manager (CEM):

Christine Pelayo

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. People who use activated prothrombin complex concentrate (aPCC; Feiba^®) to treat breakthrough bleeds while taking HEMLIBRA may be at risk of serious side effects related to blood clots.

These serious side effects include:

Thrombotic microangiopathy (TMA), a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs
Blood clots (thrombotic events), which may form in blood vessels in your arm, leg, lung, or head

Talk to your doctor about the signs and symptoms of these serious side effects, which can include:

Confusion
Stomach, chest, or back pain
Weakness
Nausea or vomiting
Swelling, pain, or redness
Feeling sick or faint
Decreased urination
Swelling of arms and legs
Yellowing of skin and eyes
Eye pain, swelling, or trouble seeing
Fast heart rate
Numbness in your face
Headache
Shortness of breath
Coughing up blood

If you experience any of these symptoms during or after treatment with HEMLIBRA, get medical help right away.

Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. If aPCC (Feiba^®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (Feiba^®) total.

Your body may make antibodies against HEMLIBRA, which may stop HEMLIBRA from working properly. Contact your healthcare provider immediately if you notice that HEMLIBRA has stopped working for you (eg, increase in bleeds).

The most common side effects of HEMLIBRA include: injection site reactions (redness, tenderness, warmth, or itching at the site of injection), headache, and joint pain. These are not all of the possible side effects of HEMLIBRA. You can speak with your healthcare provider for more information.

What else should I know about HEMLIBRA?

See the detailed “Instructions for Use” that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes.

Stop taking your prophylactic bypassing therapy the day before you start HEMLIBRA
You may continue taking your prophylactic factor VIII for the first week of HEMLIBRA

HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and create an inaccurate result. Speak with your healthcare provider about how this may affect your care.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Only use HEMLIBRA for the condition it was prescribed. Do not give HEMLIBRA to other people, even if they have the same symptoms that you have. It may harm them.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements. Keep a list of them to show your healthcare provider and pharmacist.

Before using HEMLIBRA, tell your healthcare provider about all of your medical conditions, including if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.

Since HEMLIBRA was tested in males, there is no information on whether HEMLIBRA may impact your unborn baby or breast milk. Females who are able to become pregnant should use birth control during treatment.

Side effects may be reported to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see Important Safety Information, including Serious Side Effects, as well as the HEMLIBRA full Prescribing Information and Medication Guide.

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.